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Abstract
In complement to an effective vaccine, development of potent anti-HIV microbicides remains an important priority. We
have previously shown that the miniCD4 M48U1, a functional mimetic of sCD4 presented on a 27 amino-acid stable scaffold,
inhibits a broad range of HIV-1 isolates at sub-nanomolar concentrations in cellular models. Here, we report that M48U1
inhibits efficiently HIV-1Ba-L in human mucosal explants of cervical and colorectal tissues. In vivo efficacy of M48U1 was
evaluated in nonhuman primate (NHP) model of mucosal challenge with SHIV162P3 after assessing pharmacokinetics and
pharmacodynamics of a miniCD4 gel formulation in sexually matured female cynomolgus macaques. Among 12 females,
half were treated with hydroxyethylcellulose-based gel (control), the other half received the same gel containing 3 mg/g of
M48U1, one hour before vaginal route challenge with 10 AID50 of SHIV162P3. All control animals were infected with a peak
plasma viral load of 105–106 viral RNA (vRNA) copies per mL. In animals treated with miniCD4, 5 out of 6 were fully protected
from acquisition of infection, as assessed by qRT-PCR for vRNA detection in plasma, qPCR for viral DNA detection in PBMC
and lymph node cells. The only infected animal in this group had a delayed peak of viremia of one week. These results
demonstrate that M48U1 miniCD4 acts in vivo as a potent entry inhibitor, which may be considered in microbicide
developments.
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Introduction
In complement to an effective vaccine against HIV transmis-
sion, development of potent anti-HIV microbicides remains
important strategies to consider for HIV prevention [1–2]. The
CAPRISA-004 clinical trial of 1% tenofovir gel provides the first
encouraging results from a randomized phase IIb efficacy trial
with a 39% reduced risk of HIV acquisition among HIV-
uninfected woman [3]. In this study tenofovir gel was applied in a
pericoital fashion both before and after intercourse. While
encouraging, the observed levels of protection were less than
optimal reaching only 50% in those reporting .80% adherence to
the dosing strategy. More recently trial of a once-daily dosing
regimen with tenofovir gel (VOICE) failed to demonstrate any
detectable efficacy in at risk women. These studies underline the
need to develop additional microbicide candidates with comple-
mentary or synergistic activity. Indeed, the combination of
different antiretroviral candidates acting on different steps of the
viral cycle and possessing non-overlapping resistance profiles
might be a key to increasing the levels of protection observed in
the CAPRISA-004 trial. However, only few microbicide candi-
dates, in early clinical development, have been tested for efficacy
against vaginal or rectal SIV/SHIV challenge in macaques,
providing proof of concept for accelerated clinical development.
The use of effective therapeutic drugs, such as tenofovir and
more recently dapivirine tested in phase III trial, targeting post-
entry events in the viral replication cycle (reverse transcription,
integration and viral maturation) remains attractive [3], however
the impact of their dual use in prevention and therapy on the
potential induction of resistance evolution remains controversial.
In contrast drugs that target the initial steps of viral attachment to
CD4 and one of two co-receptors (CCR5 or CXCR4) triggering
viral fusion with susceptible targets cells (entry inhibitors) are not
widely used in therapy. Some CCR5-inhibitors have demonstrated
efficacy against vaginal challenge with simian-human immunode-
ficiency virus (SHIV) in macaque models [4–6]. While active
against monotropic R5 virus exclusively utilizing the CCR5 co-
receptor, these compounds would provide no protection against
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viruses either able to utilize both the CXCR4 and CCR5 co-
receptors (dual tropic, R5X4 virus) or against monotropic X4
viruses exclusively utilizing CXCR4 for viral entry. However,
compounds active against CD4 binding would likely be active
against all three phenotypes of virus: R5, X4 and R5/X4. Few
drugs target CD4 expression, one notable exception being CADA,
yet to be evaluated in non human primate (NHP) studies [7].
Furthermore the consequence of interference with this key
immunoregulatory protein on the immune system has not been
fully characterized. In contrast the use of compounds directly
targeting the CD4 binding site in the viral envelope protein
(gp120) is less likely to have any immunomodulatory effects,
providing a promising alternative strategy. Previous studies
demonstrated that a small molecule inhibitor of gp120-CD4
interaction (BMS-378806) could protect NHP from vaginal
challenge with SHIV162P3 [8]. However, the breadth of activity
for this compound against the diversity of natural viral isolates was
too narrow to warrant further development as a microbicide
candidate.
Here we describe the evaluation of a miniCD4 mimetic,
M48U1 presented on a stable 27 amino acid scaffold. Its close
structural mimicry of CD4 endows it with broad activity across a
wider range of pseudotyped virus expressing envelope of HIV-1
isolates [9]. We report the activity of M48U1 against HIV
infection of human cervical and colorectal human tissue explants.
Furthermore we present NHP studies to access both the
pharmacokinetics and efficacy of M48U1 against vaginal chal-
lenge with SHIV162P3.
Results/Discussion
Small peptide mimetics of CD4, called miniCD4s, have been
developed by our group for a number of years through a process of
binding site transfer and further extensive optimization of a
scorpion toxin scaffold [10–11]. Structural studies confirmed the
close binding similarity between CD4 and these compounds [12–
13]. Among the most recent generation of miniCD4s, M48U1,
which no longer contains any residue common with macaque or
human CD4, was identified as possessing sub-nanomolar affinity
for gp120 with potent antiviral activity against HIV-1 subtype B
and C pseudoviruses with ED50 values ranging from 0.07 to 2 nM
and 0.4 to 37 nM, respectively [9].
These positive results prompted further assessment of the
activity of M48U1 in genital and colorectal tissue explants models.
Nonpolarized cervical and colorectal explant tissues were
pre-treated with M48U1 for 1 h at 37uC followed by exposure
to HIV-1Ba-L for 2 h in the continued presence of compound.
M48U1 inhibited mucosal explant infection in the low nanomolar
range with IC50 value of 42 nM (9–193 nM) and 4 nM (1–28 nM)
for cervical tissue (Figure 1A) and in colorectal tissue (Figure 1B),
respectively. Furthermore, M48U1 effectively inhibited the
dissemination of HIV-1Ba-L to co-cultured T cells (PM-1) by
migratory cells (dendritic cells and CD4 T cells) that emigrate out
of cervical explants during the first 24 h of culture [14] (Figure 1C)
with an IC50 of about 42 nM (11–157 nM). A small diminution in
response was seen at the highest concentration of drug tested.
Presumably this effect is due to the variability of the model or it
could also reflect some loss in solubility of M48U1 at neutral pH.
In contrast, the miniCD4 is very soluble at pH 4.5 (up to 30 mg/
mL), which is the pH of the HEC- gel formulation (see Materials
and Methods) used for in vivo challenge. M48U1 formulated in the
HEC-gel was thus tested in colorectal tissue and the HIV-1Ba-L
infection inhibition was as efficient as unformulated peptide
(Figure 1D), displaying very tight error bars. Interestingly, M48U1
retained its anti-HIV activity in this gel even when kept for several
months at 4uC. These data demonstrated that M48U1 miniCD4
was active against both direct mucosal tissue infection and
dissemination of infection by migratory dendritic cells in ex vivo
models. As some microbicides were shown to have poor
biocompatibility and to induce inflammatory responses, we first
evaluated the cytotoxicity of M48U1 using an enhanced colori-
metric MTT assay. In co-cultures of monocyte-derived dendritic
cells (MO-DC) and allogeneic CD4+ T cells, cultures of ME-180
endocervical cells [9], here, in penile tissue and in a T-cell line
(PM-1), M48U1 showed no apparent cytotoxicity at the highest
concentrations tested (Figure 2), suggesting good biocompatibility
for the miniCD4. This was in contrast to the significant toxicity
when the same tissue or cells were treated with nonoxynol-9
(Figure 2). Prior to macaque challenge studies, the activity of
M48U1 was determined in TZM-bl cells against the simian-
human chimeric virus (SHIV162P3) or pseudotyped SHIV162P3,
with IC50 values of 25 nM and 9 nM, respectively (Table 1).
These results were consistent with the nanomolar activity of
M48U1 previously reported against various HIV-1 isolates [9].
Based on these encouraging data, macaque studies were
initiated to assess the effectiveness of M48U1 against vaginal
challenge with SHIV162P3. To determine optimal dose and
appropriate time of viral challenge, formulation and pharmaco-
kinetic studies were performed in uninfected animals. Previous
reports indicated that inhibitor concentrations .1000 fold above
the in vitro IC50/90 are required to protect macaques from in vivo
mucosal challenge [4,8]. Therefore, M48U1 was formulated at
0.3% (i.e. 3 mg/g of gel – corresponding to about 1 mM) in a gel
comprising 1.5% hydroxyethylcellulose (HEC), 0.1% sorbic acid
and 2.5% glycerol, at pH 4.6. One hour after M48U1-HEC gel
application, peptide concentration in vaginal fluid was still about
75% of its concentration in the gel and this value dropped to 10%
after 4 hours (Figure 3).
For SHIV challenge studies two groups of 6 naı¨ve and sexually
mature female cynomolgus macaques (Macaca fascicularis) were
treated with medroxyprogesterone acetate (Depo-Provera, Pfizer,
30 mg) 40 days in advance. Animals received 2 g of HEC gel with
(M48U1 group) or without (placebo group) M48U1 miniCD4.
The gel was atraumatically instilled into the vaginal vault one hour
before challenge. Intravaginal challenge was carried out with a 10-
fold animal infectious dose 50% (AID50), corresponding to 2,500
tissue culture infectious dose 50% (TCID50) of SHIV162P3
(obtained from the NIH AIDS Research and Reference Reagent
Program [15]), inoculated in 50% human seminal plasma [16].
Author Summary
This report describes the protective effect of a CD4
peptide mimetic against HIV infection on human mucosal
explants and further on, when used in a microbicide gel,
against a SHIV challenge in cynomolgus macaques.
Evidence is given that our ‘‘miniprotein engineering’’
strategy, which corresponds to miniaturizing a binding
protein by transferring its binding site onto a small scaffold
protein, followed by an extensive optimization of this
miniprotein led to an active peptide with promising pre-
clinical antiretroviral activity in the case of the gp120/CD4
interaction. Five out of six animals, pre-treated with a 0.3%
miniCD4 gel were fully protected from SHIV162P3 vaginal
challenge. On the whole, we demonstrated that such a
small CD4 mimetic peptide could represent a powerful
preventive agent against sexual HIV transmission, validat-
ing miniaturized protein interface design up to the
discovery of potential new drugs.
MiniCD4 Gel Protects Macaques from SHIV Challenge
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As expected, after this stringent ‘high dose’ challenge of
progesterone-treated females, all the control animals became
infected as evidenced by detection of virus in plasma, followed by
seroconversion. In contrast, five out of six animals, treated with
0.3% M48U1 were fully protected resulting in a significant
difference compared to control animals (p = 0.0152; Fisher exact
test). For these five animals (Figure 4), plasma viral loads remained
below detection limit (60 copies of vRNA/mL) throughout the
duration of the study, they did not seroconvert and the SHIV
DNA copy numbers in lymph nodes also remained below the limit
of detection (10 copies/million cells). The plasma of the single
animal (# 19302) infected in the M48U1 gel group was fully
evaluated for possible miniCD4-resistant viruses. Plasma was
collected 21 days after challenge, and the extracted virus genes
were sequenced and pseudotyped. All the breakthrough viruses
tested were fully susceptible to M48U1 in TZM-bl assay. Some
mutations were observed (notably the Q507R mutation) but none
of them were shown to be responsible for any form of resistance.
We don’t find any reported resistance mutations [17] in such
breakthrough viruses. In addition, protected animals did not differ
from control animals in terms of MHC haplotypes associated with
control of viremia [18–20] (Supplemental Figure S1). Mucosal
treatments could potentially induce local inflammatory response
which may interfere with infection and microbicide effect.
Quantities of cytokines and chemokines in vaginal fluids of
macaques 25 h after treatment with placebo- or M48U1-gel were
not significantly different (Supplemental Figure S2), except lower
G-CSF (60%) in M48U1- vs placebo-treated animals. However, it
is possible that imperfect gel delivery in the infected animal or the
0.3% dosing of M48U1 were not sufficient to achieve 100%
protection. Further dose/response studies are required to elimi-
nate this last possibility.
In conclusion, we have demonstrated that the CD4 mimetic
M48U1 miniprotein can efficiently protect macaques from SHIV
challenge, indicating that this small peptide, acting as a fusion
entry inhibitor, could represent a new preventive agent against
sexual transmission of HIV-1 when formulated as a microbicide.
Thanks to its stably folded scaffold, this peptide possesses high
stability and resistance to temperature and protease degradation.
Contrary to other entry inhibitors, miniCD4 targets the virus and
not a human receptor. Moreover, it is not used in current HIV
therapy. This might provide a significant advantage as it may
prevent the spread of viruses that become resistant to current
treatments. Our study provided evidence that the molecules,
Figure 1. Inhibition of HIV-1Ba-L infection by M48U1 in genital tissue explant models. Inhibition of HIV-1Ba-L infection of cervical (A) and
colorectal (B) tissue explants pre-treated with M48U1. (C) Inhibition of HIV-1Ba-L trans-infection of PM-1 T cells co-cultured with cells migrating out of
cervical tissue explants treated with M48U1. (D) Inhibition of HIV-1Ba-L infection of colorectal tissue explants treated with M48U1 coming from
dilution of the formulation at 0.3% in the gel used for in vivo challenge, comprising 1.5% hydroxyethylcellulose (HEC), 0.1% sorbic acid and 2.5%
glycerol kept at 4uC during more than one year. Viral replication was assessed by measuring p24 production in supernatants at days 10 (circle, dotted
line) and 15 (triangle, solid line). The percentage of inhibition was normalized relative to the p24 values obtained for explants not exposed to HIV-1Ba-
L (0% infectivity) and for explants exposed to HIV-1Ba-L in the absence of M48U1 (100% infectivity). Data points correspond to mean values and error
bars represent the standard error of the mean (SEM) from three independent experiments performed in triplicates.
doi:10.1371/journal.ppat.1003071.g001
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which interact with the CD4-binding site of HIV envelope, are
highly potent at blocking HIV entry and represent valuable
microbicide candidates. Finally, these results show that ‘‘our
miniprotein engineering strategy’’, which corresponds to minia-
turizing a protein by transferring its binding site onto a small
scaffold followed by optimization, could represent an effective
method to develop new binding-inhibitory drugs with modified
physicochemical and pharmacokinetic properties.
Materials and Methods
Ethics statement
Adult cynomolgus macaques (Macaca fascicularis) were imported
from Mauritius and housed in the facilities of the ‘‘Commissariat a`
l’Energie Atomique et aux Energies Alternatives’’ (CEA, Fonte-
nay-aux-Roses, France). Non-human primates (NHP, which
includes M. fascicularis) are used at the CEA in accordance with
French national regulation and under national veterinary inspec-
tors (CEA Permit Number A 92-032-02). The CEA is in
compliance with Standards for Human Care and Use of
Laboratory of the Office for Laboratory Animal Welfare (OLAW,
USA) under OLAW Assurance number #A5826-01. All exper-
imental procedures were also conducted accordingly to European
guidelines for animal care (European directive 86/609, ‘‘Journal
Officiel des Communaute´s Europe´ennes’’, L358, December 18,
1986). The use of NHP at CEA is also in accordance with
recommendation with the newly published European Directive
(2010/63, recommendation Nu9). No suffering was specifically
associated with vaginal treatment of macaques. The animals were
used under the supervision of the veterinarians in charge of the
animal facility. This study was part of the European Microbicides
Project (EMPRO, EU contract number LSHCT-2004-503558)
which NHP studies were accredited by ethical committee ‘‘Comite´
Re´gional d’Ethique pour l’Expe´rimentation Animale Ile-De-
France Sud’’ under statement number 04-001 of April 7th, 2004.
M48U1 synthesis
The M48U1 peptide containing a p-(cyclohexylmethyloxy)phe-
nylalanine residue at position 23 was synthesized at Pepscan Presto
Inc. (Lelystad, The Netherlands) by solid phase peptide synthesis
and purified after refolding by reverse-phase high performance
liquid chromatography as described elsewhere [21].
Viruses
SHIV162P3 virus was obtained through AIDS Research and
Reference Reagent Program, NIAID, NIH from Drs Janet
Harouse, Cecilia Cheng-Mayer, Ranajit Pal and the DAIDS,
NIAID [15]. HIV-1Ba-L, provided by this Program was passaged
through activated PBMC for 11 days.
Model explant study
Cervical tissue was obtained from patients undergoing planned
therapeutic hysterectomy at St. George’s Hospital in London,
United Kingdom. Surgically resected specimens of colorectal
Figure 2. Viability assay to evaluate the cytotoxicity of M48U1 on mucosal tissue explants and PM-1 T cells. Penile tissue explants
(blank bars) and PM-1 cells (grey bars) were exposed to 10-fold dilutions of M48U1 for 24 h at 37uC. After removing the peptide, the tissue explants
and the cells were incubated with MTT for 2 h. Then the viability was determined by measuring the formazan release. Nonoxynol-9 microbicide
(500 ng/mL) was employed as cytotoxic reference, while the untreated control was assumed as 100% of viability. Data points correspond to mean
values and error bars represent the standard error of the mean (SEM) from two independent experiments performed in triplicates.
doi:10.1371/journal.ppat.1003071.g002
Table 1. Inhibition activity of M48U1 in TZM-bl exposed to
HIV-1SF162, SHIV162P3 or pseudovirus (PV) containing HIV-1SF162
or SHIV162P3 envelope.
Virus/pseudovirus IC50 (nM)
HIV-1SF162 0.95
SHIV162P3 25
Ratio SHIV/SF = 26
PV HIV-1SF162 0.85
PV SHIV162P3 9.36
Ratio SHIV/SF = 11
doi:10.1371/journal.ppat.1003071.t001
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tissue were collected at St. George’s Hospital, London, United
Kingdom. Penile tissue (glans) was obtained from individuals
undergoing gender reassignment surgery at Charing Cross
Hospital. All tissues were collected after signed informed consent
was received from all patients and under protocols approved by
the Local Research Ethics Committee (National Research Ethic
Service NHS). On arrival in the laboratory, resected tissue was cut
into 2–3 mm3 explants comprising both epithelial and stromal
tissue or muscularis mucosae, depending on the tissue, as
described previously [14,22].
Cervical explants were cultured in RPMI 1640 medium
supplemented with 2 mM L-glutamine, 10% fetal calf serum
(FCS), and antibiotics (100 U/mL of penicillin, 100 mg/mL of
streptomycin) Cervical explants were pre-incubated with ten-fold
dilutions of M48U1 for 1 h. Tissue was then exposed to HIV-1Ba-L
(at 104 TCID50/mL equivalent to an MOI of 1) for 2 h and then
washed 4 times with PBS to remove compound and/or virus.
Explants were then transferred to a fresh tissue culture plate [14].
Following overnight incubation, tissue explants were moved to a
fresh tissue culture plate and migratory cells left in the original
plate were washed twice with PBS and co-cultured with 46104
PM-1 cells/well without compound in 96-well plates for trans-
infection assays. Tissue explants and cellular co-cultures were
cultured for 15 days in the absence of compound.
Colorectal explants were maintained with DMEM containing
10% FCS, 2 mM L-glutamine and antibiotics (100 U/mL of
penicillin, 100 mg/mL of streptomycin, 80 mg/mL of gentamicin).
Colorectal explants were incubated with ten-fold dilutions of
M48U1 for 1 h before exposure to HIV-1Ba-L (at 10
3 TCID50/mL
equivalent to an MOI of 1). Explants were then washed 4 times
with PBS to remove unbound compound and/or virus. Tissue
explants were then transferred onto gelfoam rafts (Welbeck
Pharmaceuticals, UK) and cultured for 15 days as previously
described [22] in the absence of compound.
For all tissue explant models and migratory/PM-1 cell co-
cultures approximately 50% of the supernatants of explants and
cellular co-cultures were harvested every 2 to 3 days following re-
fed with fresh media in the presence or absence of compound. The
extent of virus replication was determined by measuring the p24
antigen concentration in supernatants (HIV-1 p24 ELISA, AIDS
Vaccine Program, National Cancer Institute, Frederick, MA) [22].
All culture and incubations were carried out at 37uC in an
atmosphere containing 5% CO2.
Viability assay on tissue explants and PM-1 T cells
Penile tissues and PM-1 T cells were incubated in complete
RPMI medium supplemented with ten-fold dilutions of M48U1
for 24 h at 37uC. Nonoxynol-9 microbicide (tested at 500 ng/mL)
was employed as cytotoxic reference. The compounds were
removed and the tissue explants and cells were incubated for 2 h
in medium containing 500 mg/mL of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT). For tissue, after releas-
ing the formazan in ethanol overnight, cytotoxicity was deter-
mined by measuring the optical density of the purple formazan
Figure 3. Pharmacokinetic studies in non-infected macaques. Mean concentration of M48U1 miniCD4 measured in the vaginal fluid of two
cynomolgus macaques following vaginal administration of a single 2 g sample of 1.5% hydroxyethylcellulose (HEC) gel containing M48U1 at 3 mg/g
(about 1 mM). The vaginal fluids were sampled before and 1 h, 4 h, 6 h, 24 h, 48 h and 72 h after gel application and analyzed by MS spectra with an
internal reference for M48U1 quantification. The bars represent the standard error of the mean (SEM) of the three assay replicates.
doi:10.1371/journal.ppat.1003071.g003
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product at 570–690 nm using Synergy HT multi-detection
microplate reader. For PM-1 cells, the absorption of the formazan
product was determined after lysis of the cells.
Evaluation of sensitivity of HIV-1SF162 and SHIV162P3 to
M48U1 in the TZM-bl assay
Primary HIV-1SF162 or SHIV162P3 were briefly amplified in
PHA-IL2 activated human PBMC. Corresponding Env expressing
constructs were prepared by DNA amplification of the complete
Env gene from PBMC co-cultures and subsequent cloning into
pSV7d or pcDNA4/TO expression vector (Invitrogen BV,
Groningen, The Netherlands). Sequencing of the pseudovirus
construct and phylogenetic analysis of the complete gp160
confirmed the relation between the pseudovirus and the associated
original virus.
Pseudoviruses were generated in a 24-well plate by co-
transfection of 26105 human embryonic kidney (HEK) 293T
cells (obtained from ATCC) with pNL4-3. LucR-E- (400 ng, NIH
AIDS Research and Reference Reagent Program) and HIV-1SF162
or SHIV162P3 Env expressing plasmid (1 mg) using the Calcium
phosphate method (ProFection Mammalian Transfection Systems,
Promega Benelux BV, Leiden, The Netherlands). After 24 h, the
culture medium (Dulbecco’s Minimum Essential Medium -
DMEM) was replaced with medium containing 1 mM sodium
butyrate and incubated for another day. Two days post-
transfection, pseudoviruses were harvested and passed through
Figure 4. Protection of macaques against vaginal SHIV challenge by pretreatment with M48U1 gel. Viral loads in placebo (A) and
M48U1-gel (B) treated macaques. One hour after gel application, animals were challenged with 10 AID50 of SHIV162P3. Macaques were monitored
regularly for plasma viremia for 78 days. The area below the ordinate axis break represents values below the 60 RNA copies/mL detection limit (BD –
below detection).
doi:10.1371/journal.ppat.1003071.g004
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Millex 0.45 mm filters. 10% fetal bovine serum (FBS) was added to
filtered pseudoviruses, then the suspensions were aliquoted in
1 mL tubes and stored at 280uC until use.
Adherent CD4 and CCR5 expressing TZM-bl cell line with a
luciferase reporter gene under HIV LTR control (NIH AIDS
Research and Reference Reagent Program) [23] was cultured in
DMEM containing 1% L-glutamine, 10% heat-inactivated FBS,
and 50 mg/mL gentamicin.
Primary viruses and pseudoviruses were preliminarily titrated in
TZM-bl cells and used at a concentration that resulted in 105
relative light units (RLU). The inhibitory activity of M48U1 against
either HIV-1SF162, SHIV162P3 or corresponding pseudoviruses was
measured as follows: 50 mL of (pseudo)virus suspension and 50 mL
of a serial dilution of M48U1 or 50 mL medium (negative control)
were pre-incubated for 30 min. Next, 100 mL of TZM-bl cells (at
105/mL) supplemented with 30 mg/mL DEAE dextran were added
to each well and the 96-well plates were incubated for 48 h.
Subsequently, 120 mL of supernatants were removed and 75 mL of
Steadylite HTS (Perkin Elmer, Life Sciences, Zaventem, Belgium)
were added. Next the luciferase activity (proportional to the amount
of infectious virus particles) was measured using a TriStar LB941
luminometer (Berthold Technologies GmbH & Co.KG., Bad
Wildbad, Germany) and expressed as relative light units (RLU).
Finally, the inhibitory activity was calculated in GraphPad Prism
5.03 using non-linear regression (GraphPad Software, San Diego,
CA, USA). All cultures and incubations were carried out at 37uC in
5% CO2 atmosphere.
Gel formulation of M48U1
M48U1 was formulated at 3 mg/g in an aqueous vehicle
containing sorbic acid (0.1%), glycerol (2.5%) and gelling polymer
hydroxyethylcellulose (HEC, final concentration 1.5%). The pH of
the gels was 4.660.1, within the range of the normal, premen-
opausal vaginal pH. The osmolality (29263 mOsm/kg) fell within
the range of physiological fluids, thereby avoiding safety issues
with hyperosmolar microbicide gels. Placebo gels were prepared in
the same way but did not contain any M48U1.
Macaque Pharmacokinetic (PK) study
Two grams of the previously described gel containing M48U1
at 3 mg/g were injected, using a French catheter connected to
ready-to-use syringe, into the vaginal vault of two naı¨ve female
cynomolgus macaques (Macaca fascicularis). Vaginal fluids were
sampled using Weck-Cel surgical sponges before and 1 h, 4 h, 6 h,
24 h, 48 h and 72 h after gel application. Only one sampling was
performed for each animal. Multiple samplings would increase the
statistical analysis but would result in a decrease of the miniCD4
concentration in the vagina for the next samplings. The miniCD4
concentration of each sample was independently assessed 3 times
and the resulting data was represented by mean and standard
error of the mean (SEM). To determine these concentrations, MS
spectra were registered with a 4800 MALDI-TOF/TOF mass
spectrometer (Applied Biosystems, Foster City, USA) using an
internal standard consisting of M48U3 (similar peptide with a
slight difference of residue at position 23) [9].
Macaque challenge study
Two groups of 6 naı¨ve female cynomolgus macaques (Macaca
fascicularis), treated with 30 mg medroxyprogesterone acetate
(Depo-Provera, Pfizer) 40 days before the challenge, were
atraumatically injected into the vaginal vault 1 h before challenge
with 2 g of HEC gel with (M48U1 group) or without (placebo
group) M48U1. Intravaginal challenge was carried out with 10
AID50 of SHIV162P3, corresponding to 2,500 TCID50, inoculated
in 50% human seminal plasma [16].
Blood was collected in EDTA tubes at different time points,
from 20 days before to 78 days after infection. Plasma viremia for
each sample was evaluated using quantitative RT-PCR for
measurement of viral RNA copy numbers. Detection limit of this
method is 60 RNA copies/mL and quantification limit is 300
RNA copies/mL [24]. The SHIV DNA copy numbers in lymph
nodes were also measured in animals with undetectable plasma
viremia by quantitative PCR, using primers amplifying the gag
regions of SHIV. Detection limit is 10 copies per million of cells
[25].
Vaginal fluids were collected 24 h after viral challenge, i.e. 25 h
after intravaginal treatment. Cytokines and chemokines (G-CSF,
GM-CSF, IFN-c, IL-1b, IL-1Ra, IL-2, IL-5, IL-6, IL-8, IL-10, IL-
12/23(p40), IL-17, IL-18, MCP-1, MIP-1a, MIP-1b, TNF-a) were
quantified using non-human primate Milliplex kit (Millipore) and
a Bioplex2000 instrument (Biorad).
Supporting Information
Figure S1 MHC haplotypes of the Mauritian cynomol-
gus macaques included in the study. MHC haplotypes were
determined by microsatellite analysis as described elsewhere [26].
M1 to M6 haplotypes were identified in these macaques (M1,
black; M2, red; M3, blue; M4, green; M5, yellow; M6, grey).
White boxes indicate variant microsatellite allele sizes relative to
the expected haplotype. These rare variants generally differ by the
addition or loss of a single repeat unit.
(TIF)
Figure S2 Cytokine and chemokine in macaque vaginal
fluids after placebo- or M48U1 gel intravaginal admin-
istration. Vaginal fluids were collected 25 h after intravaginal
application of either placebo- or M48U1-gel, i.e. 24 h after
SHIV162P3 challenge. Individual data and mean with standard
error of the mean (SEM) are presented. Group comparison was
performed using non parametric Mann-Whitney test. Elevated
TNF-a concentrations (not significant) were observed in two
M48U1-treated animals (#16866: 26 pg/mL and #19831:
174 pg/mL). Both animals were protected from SHIV acquisition,
suggesting that such TNF-a levels were not associated with
enhancement of infection.
(TIF)
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